HSDT Helius Medical: Accounting Value per Share

Helius Medical Technologies (HSDT) - corporate logo

Does Helius Medical (HSDT) possess potential given the promotion of the PoNS system for combating multiple sclerosis? The book value per common share helps assess real assets, with the 2.87 mark reflecting the latest data. Stable demand for portable neurostimulators creates predictable revenue. The strategy relies on partnerships with clinics to implement restorative therapy.

Helius Medical Technologies Inc. (HSDT) Equity per Share: for the period 07/04/2022 - 10/27/2026

Helius Medical Technologies, Inc. - analytical breakdowns and key metrics (HSDT)

- price and consensus price forecast:
Stock Price Helius Medical Technologies Inc.|HSDT - Broker Consensus Forecast
- market capitalization data:
Market Valuation Helius Medical Technologies, Inc.|HSDT - Aggregate Business Value
- book capitalization data:
Net Assets per Single Share Helius Medical Technologies|HSDT - Accounting Capitalization|Market Capitalization to Book Value Ratio heliusmedical.com|HSDT - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Helius Medical|HSDT - Long-Term Debt to Capital|Short-Term Debt to Equity Helius Medical Technologies Inc.|HSDT - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Helius Medical Technologies, Inc.
Fundamental company valuation:heliusmedical.com, HSDT
Manufactured products of Helius Medical Technologies Inc.

For Helius Medical (HSDT), the bps metric reflects the net asset value per share, serving as an indicator of intrinsic stability during the commercialization of neurostimulators. The bps trend demonstrates a gap between real capital and the market price, confirming a sufficient liquidity cushion for business development while awaiting the approval of insurance reimbursements.

Competitors of Helius Medical (HSDT)

Biogen Corp (BIIB) - Book Value per Share|Neurocrine Corp (NBIX) - Equity per Share|RGC - Accounting Value per Share|AXSM (axsome.com) - Book Price of a Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Xenon Pharmaceuticals Inc.|Viking Pharma - Book Value per Share|Net Asset Value per Share Supernus Corp SUPN|Accounting Value per Share CPRX (Catalyst Pharmaceuticals)|denalitherapeutics.com - Book Value per Share|Net Assets per Single Share Harmony Biosciences Holdings, Inc. (HRMY)|BHVN: Accounting Value of a Share|Net Assets per Single Share AMLX|Trevi Corp (TRVI) - Net Asset Value per Share|PRAX - Book Value per Share|Accounting Value of a Share anavex.com|CeriBell - Book Value per Share|Net Asset Value per Share PRTA (Prothena Corporation)|Net Assets per Single Share Alector ALEC|Net Assets per Single Share Annexon Biosciences Inc. ANNX|Book Value per Share OMER (Omeros Corp.)|neurogene.com (NGNE) - Net Assets per Share|ACIU: Accounting Value per Share|VYGR (Voyager Therapeutics Inc) - Book Value per Share|NMRA: Net Assets per Single Share|Net Assets per Share Scilex Holding Company, Inc. (SCLX)|Tevogen Bio Holdings (TVGN) - Accounting Value per Share|Accounting Value of a Share ACOG (alphacognition.com)|Cognition Therapeutics - Net Assets per Single Share|Accounting Value per Share Inhibikase Therapeutics Inc IKT|SAVA (Cassava) - Book Value per Share|ASRT - Net Asset Value per Share|Book Value per Share coyatherapeutics.com|Vistagen (VTGN) - Equity per Share|OVID: Book Value per Share|Net Assets per Share Acumen Pharmaceuticals Inc.|Book Value per Share CRVO (CervoMed Inc)|Accounting Value per Share alteritytherapeutics.com (ATHE)|Book Value per Share CLNN (Clene)|PepGen Inc - Book Value per Share|JUNS - Net Assets per Single Share|RLMD - Net Assets per Single Share|Book Value per Share Annovis Bio Corp ANVS|GRCE (Grace Therapeutics) - Accounting Value of a Share|AIFF: Net Assets per Single Share|Net Assets per Share ANEW Medical, Inc.|Book Value per Share NeuroSense Therapeutics NRSN|Equity per Share Reviva Pharmaceuticals Holdings Inc. RVPH|Accounting Value per Share MetaVia (MTVA)|NeurAxis Inc - Book Price of a Share|Passage Bio Corp (PASG) - Net Assets per Single Share|NEUP - Equity per Share|Book Value per Share NERV|Net Asset Value per Share Athira Pharma Inc|ADXN (Addex Therapeutics, Ltd.) - Accounting Value per Share|Book Value per Share ALZN|Cyclerion Therapeutics (CYCN) - Net Assets per Single Share|Accounting Value of a Share PTIX (protagenic.com)|KTTA: Net Assets per Single Share|Net Asset Value per Share Cortigent Inc CRGT|Book Value per Share Avenue Therapeutics, Inc (ATXI)|BCLI - Accounting Value of a Share|Book Value per Share CARA|CHRO (chromocell.com) - Net Asset Value per Share|Net Assets per Single Share Eliem Therapeutics, Inc.|Net Assets per Single Share Intra-Cellular|LBPH (Longboard Pharma) - Book Value per Share|Net Assets per Share Marinus Pharma MRNS|Accounting Value per Share NKGN (NKGen Biotech, Inc.)|neurobopharma.com - Book Value per Share|Net Assets per Single Share SAGE (Sage Therapeutics)|Synaptogenix Inc. (SNPX) - Net Assets per Share|Accounting Value per Share Trevena, Inc TRVN|VIGL (Vigil Neuroscience, Inc.) - Accounting Value of a Share|Net Assets per Single Share WENA|Accounting Value per Share cerevel.com